ION expands ETF trading capabilities with Tradeweb integration
NEW YORK - Morgan Stanley & Co. LLC disclosed on Wednesday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, according to a regulatory filing with the Irish Takeover Panel.
The investment bank, acting as an exempt principal trader with recognized intermediary status in a client-serving capacity, reported transactions conducted on November 17, 2025. The disclosure was made under Rule 38.5(a) of the Irish Takeover Panel Act.
According to the filing, Morgan Stanley purchased 745,501 ordinary shares of Avadel Pharmaceuticals at prices ranging from $22.8750 to $23.3250 per share. The firm also sold 745,857 shares at prices between $22.8750 and $23.3312 per share.
The disclosure identifies Morgan Stanley as connected to Avadel Pharmaceuticals in relation to an unspecified corporate action. No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the filing.
The bank confirmed in the disclosure that there are no indemnity arrangements, agreements, or understandings relating to options or derivatives involving Avadel Pharmaceuticals securities.
This information was submitted to the Regulatory Information Service as required by Rule 38 of the Irish Takeover Rules. The disclosure was made through RNS, the news service of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.